Samsara BioCapital, L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-27 6:17 pm Sale |
2024-11-18 | 13D | Syros Pharmaceuticals, Inc. SYRS |
Samsara BioCapital, L.P. | 707,114 2.600% |
-1,808,409 (-71.89%) |
Filing |
| 2023-12-26 5:19 pm Purchase |
2023-12-21 | 13D | Syros Pharmaceuticals, Inc. SYRS |
Samsara BioCapital, L.P. | 2,515,523 9.500% |
909,977 (+56.68%) |
Filing |
| 2023-10-20 4:15 pm Purchase |
2023-01-15 | 13D | Syros Pharmaceuticals, Inc. SYRS |
Samsara BioCapital, L.P. | 1,605,546 7.500% |
1,605,546 (New Position) |
Filing |